Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases.
Fujisawa Y, Namikawa K, Yoshino K, Kiniwa Y, Ito T, Kato H, Matsushita S, Hoashi T, Nakamura Y, Yoshikawa S, Miyagawa T, Asai J, Matsuya T, Fukushima S, Kato J, Takenouchi T, Uchi H, Masuzawa M, Yanagi T, Maekawa T. Fujisawa Y, et al. Among authors: namikawa k. Br J Dermatol. 2023 Jul 17;189(2):223-250. doi: 10.1093/bjd/ljad114. Br J Dermatol. 2023. PMID: 37017027 No abstract available.
Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: a multi-institutional study of 450 patients in Japan.
Namikawa K, Yamazaki N, Nakai Y, Ihn H, Tomita Y, Uhara H, Takenouchi T, Kiyohara Y, Moroi Y, Yamamoto Y, Otsuka F, Kamiya H, Iizuka H, Hatta N, Kadono T. Namikawa K, et al. J Dermatol. 2012 Feb;39(2):130-7. doi: 10.1111/j.1346-8138.2011.01318.x. Epub 2011 Sep 28. J Dermatol. 2012. PMID: 21950448
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Yamazaki N, Uhara H, Fukushima S, Uchi H, Shibagaki N, Kiyohara Y, Tsutsumida A, Namikawa K, Okuyama R, Otsuka Y, Tokudome T. Yamazaki N, et al. Among authors: namikawa k. Cancer Chemother Pharmacol. 2015 Nov;76(5):969-75. doi: 10.1007/s00280-015-2870-0. Epub 2015 Sep 25. Cancer Chemother Pharmacol. 2015. PMID: 26407818 Free PMC article. Clinical Trial.
Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan.
Tsutsumida A, Takahashi A, Namikawa K, Yamazaki N, Uhara H, Teramoto Y, Takenouchi T, Fukushima S, Yokota K, Uehara J, Matsushita S, Shibayama Y, Hatta N, Masui Y, Uchi H, Fujisawa Y, Ogata D. Tsutsumida A, et al. Among authors: namikawa k. Int J Clin Oncol. 2016 Aug;21(4):796-800. doi: 10.1007/s10147-015-0944-y. Epub 2016 Jan 13. Int J Clin Oncol. 2016. PMID: 26759315
Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.
Fujiwara Y, Yamazaki N, Kiyohara Y, Yoshikawa S, Yamamoto N, Tsutsumida A, Nokihara H, Namikawa K, Mukaiyama A, Zhang F, Tamura T. Fujiwara Y, et al. Among authors: namikawa k. Invest New Drugs. 2018 Apr;36(2):259-268. doi: 10.1007/s10637-017-0502-8. Epub 2017 Sep 7. Invest New Drugs. 2018. PMID: 28879519 Clinical Trial.
Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON).
Namikawa K, Tsutsumida A, Mizutani T, Shibata T, Takenouchi T, Yoshikawa S, Kiyohara Y, Uchi H, Furue M, Ogata D, Tsuchida T, Yamazaki N. Namikawa K, et al. Jpn J Clin Oncol. 2017 Jul 1;47(7):664-667. doi: 10.1093/jjco/hyx063. Jpn J Clin Oncol. 2017. PMID: 29136453 Free PMC article. Clinical Trial.
Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
Yamazaki N, Tsutsumida A, Takahashi A, Namikawa K, Yoshikawa S, Fujiwara Y, Kondo S, Mukaiyama A, Zhang F, Kiyohara Y. Yamazaki N, et al. Among authors: namikawa k. J Dermatol. 2018 Apr;45(4):397-407. doi: 10.1111/1346-8138.14210. Epub 2018 Feb 5. J Dermatol. 2018. PMID: 29399853 Free PMC article. Clinical Trial.
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, Takatsuka S, Koga H, Wada N, Minami H, Hatsumichi M, Asada S, Namba Y, Yamazaki N. Namikawa K, et al. Eur J Cancer. 2018 Dec;105:114-126. doi: 10.1016/j.ejca.2018.09.025. Epub 2018 Nov 15. Eur J Cancer. 2018. PMID: 30447539 Free article. Clinical Trial.
287 results